Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant *Pseudomonas aeruginosa*\(^\dagger\)

Amy L. Pakyz,\(^1\) Michael Oinonen,\(^2\) and Ronald E. Polk\(^1\)*

Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia,\(^1\) and University HealthSystem Consortium, Oak Brook, Illinois\(^2\)

Received 18 November 2008/Returned for modification 11 December 2008/Accepted 21 February 2009

Many hospital antimicrobial stewardship programs restrict the availability of selected drugs by requiring prior approval. Carbapenems may be among the restricted drugs, but it is unclear if hospitals that restrict availability actually use fewer carbapenems than hospitals that do not restrict use. Nor is it clear if restriction is related to resistance. We evaluated the relationship between carbapenem restriction and the volume of carbapenem use and both the incidence rate and proportion of carbapenem-resistant *Pseudomonas aeruginosa* isolates from 2002 through 2006 in a retrospective, longitudinal, multicenter analysis among a consortium of academic health centers. Carbapenem use was measured from billing records as days of therapy per 1,000 patient days. Hospital antibiograms were used to determine both the incidence rate and proportion of carbapenem-resistant *P. aeruginosa* isolates. A survey inquired about restriction policies for antibiotics, including carbapenems. General linear mixed models were used to examine study outcomes. Among 22 hospitals with sufficient data for analysis, overall carbapenem use increased significantly over the 5 years of study (\(P < 0.0001\)), although overall carbapenem resistance in *P. aeruginosa* did not change. Hospitals that restricted carbapenems (\(n = 8; 36\%\)) used significantly fewer carbapenems (\(P = 0.04\)) and reported lower incidence rates of carbapenem-resistant *P. aeruginosa* (\(P = 0.01\)) for all study years. Fluoroquinolone use was a potential confounder of these relationships, but hospitals that restricted carbapenems actually used fewer fluoroquinolones than those that did not. Restriction of carbapenem is associated with both lower use and lower incidence rates of carbapenem resistance in *P. aeruginosa*.

Hospital antimicrobial stewardship programs (ASPs) attempt to improve antibacterial prescribing, commonly using formulary restrictions and by requiring preauthorization (7). Carbapenems are restricted in some hospitals for treatment of gram-negative bacterial infections resistant to first-line drugs, although carbapenem resistance among *Pseudomonas aeruginosa* and *Enterobacteriaceae* is increasing (3, 14, 18–20).

Individual hospitals have reported improvement in bacterial susceptibilities to carbapenems after implementing ASPs that restricted carbapenem use (1, 11, 22). However, these “before and after” study designs have been criticized, and it is not known if the results are generalizable (6). There are no multihospital investigations that have assessed the effect of carbapenem restriction on carbapenem use and carbapenem-resistant *P. aeruginosa* over multiple years. In this study we evaluated the association between carbapenem restriction in academic health centers and the volume of carbapenem use and both the incidence rate and proportion of carbapenem-resistant *P. aeruginosa* from 2002 through 2006.

(This study was presented in part at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2007.)

\(^{\dagger}\) Published ahead of print on 9 March 2009.

\(^{*}\) Corresponding author. Mailing address: VCU School of Pharmacy, MCV Campus, 410 North 12th Street, P.O. Box 980533, Richmond, VA 23298-0533. Phone: (804) 828-8317. Fax: (804) 828-8359. E-mail: rpolk@vcu.edu.

\(^{1}\) Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia, and University HealthSystem Consortium, Oak Brook, Illinois.

\(^{2}\) Published ahead of print on 9 March 2009.

MATERIALS AND METHODS

Data source. The University HealthSystem Consortium (UHC) consists of 102 academic hospitals in the United States; some UHC members also participate in the Clinical Resource Manager (CRM) database from which medication utilization data for this study was obtained. The number of hospitals subscribing to the CRM database that also agreed to contribute data to this investigation increased from 23 hospitals in 2002 to 35 hospitals in 2006. Additional details of the UHC network are described in a recent publication that examined trends in antimicrobial drug use within the network (12).

Assessment of antibacterial restriction and antibiogram construction. A 12-question survey requesting information regarding the hospital’s antibacterial stewardship program policies between the years 2002 and 2006 was sent via e-mail in 2006 and 2007 to a pharmacist or physician infectious diseases specialist at each hospital for whom we had contact information (\(n = 30\)). One survey question asked if a prior approval restriction policy for select antibacterials was used and if so, for which drugs. Other questions inquired about the methods used to construct the hospital’s antibiogram, including whether duplicate patient isolates were removed when compiling resistance rates. We also asked if there had been any changes in the ASP policies over these years. In this investigation, hospitals that stated that they restricted carbapenem use over the study period were contrasted to hospitals that did not.

Assessment of resistance. Antibiograms were requested for years 2002 to 2006. Only antibiograms that included a full calendar year of susceptibility data from all clinical sources were used. From these we estimated two measures of imipenem/meropenem-resistant *P. aeruginosa*: (i) the proportion of resistant isolates (percent resistant) and (ii) the incidence rate of resistance (number of resistant isolates/1,000 discharges). Schwaber et al. argued that measuring incidence rates of resistance is the more appropriate measure for assessing the relationship between antibacterial use and resistance (17).

Assessment of antibacterial use. Yearly carbapenem use (meropenem and imipenem) with adult patients discharged between 1 January 2002 through 31 December 2006 was obtained from billing records as previously described; antibacterial use was validated at one of these hospitals (12). We did not measure use of ertapenem. Carbapenem use was expressed as days of therapy per 1,000 patient days (DOT/1,000 PD). If a patient received a single dose of an antibac-
terial drug on a given day, whether or not multiple doses are usually administered, it was registered as 1 DOT. The advantages of DOT as a measure of antibacterial use compared with the defined daily dose (DDD) have recently been reported (15).

Because fluoroquinolone use has been reported to be a risk factor for carbapenem resistance in P. aeruginosa (5, 8, 13, 14, 20), we also measured total fluoroquinolone use in hospitals where carbapenems were restricted and compared this to total fluoroquinolone use in hospitals that did not restrict carbapenems. The fluoroquinolones in this analysis included ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin, and their use was measured as previously described (12).

**Statistical analysis.** The following three different general linear mixed models were used to examine three outcomes over the study period among hospitals that did and did not restrict carbapenems: (i) carbapenem use and both the (ii) proportion and (iii) incidence rates of carbapenem-resistant isolates for P. aeruginosa. Use of the mixed model enabled examination of relationships across time, with missing data points (10). We also used linear regression to evaluate univariate relationships between carbapenem and fluoroquinolone use and incidence rates of carbapenem-resistant P. aeruginosa. A P value of <0.05 was considered statistically significant. The statistical software used was JMP (version 7.0; SAS Institute, Cary, NC). The Institutional Review Board at Virginia Commonwealth University approved this investigation.

**RESULTS**

A total of 25 hospitals responded to the ASP policy survey; of these, 22 hospitals provided data regarding carbapenem use and carbapenem resistance (both proportion and number of resistant isolates) for at least 2 years. Of 110 possible data points (22 hospitals and 5 years of data), there were 94 (85%) carbapenem use data points and 89 (81%) data points for incidence rates of resistance. Hospitals represented the following regions: Mid-Continent (5 hospitals); Midwestern (4 hospitals); Mid-Atlantic (4 hospitals); Southeastern (5 hospitals); Western (3 hospitals); and New England (1 hospital). Mean bed size was 427 (±139), and mean age for all patients in all hospitals was 50 (±4.0) years.

Of these 22 hospitals, 8 (36%) stated that they restricted carbapenem use by requiring prior approval (1 hospital required approval after 48 h); the remaining 14 did not. None of the hospitals reported changes in their carbapenem restriction policy over the 5 years of the study. Most hospitals used both meropenem and imipenem. For example in 2004, 15 of 20 reporting hospitals used more imipenem than meropenem, and 3 of these used imipenem exclusively. For the same year, 5 hospitals used more meropenem than imipenem, and 2 of these used meropenem exclusively.

Fifteen hospitals removed duplicate isolates when compiling susceptibility data, three did not; information regarding duplicate isolate removal was not available for four.

Overall carbapenem use in these 22 hospitals increased significantly over time, from a mean of 23.3 DOT/1,000 PD in 2002 to 21.3 (2003), 24.7 (2004), 27.8 (2005), and 31.4 DOT/1,000 PD in 2006 (P < 0.0001). (These 22 hospitals are not identical to the 22 hospitals reported in reference 12.) The overall proportion of carbapenem-resistant P. aeruginosa isolates did not change significantly over time; it increased from a mean of 18% in year 2002 to 19% (2003), 20% (2004), 23% (2005), and 22% in 2006 (P = 0.21). In addition, the overall incidence rate of resistant P. aeruginosa isolates did not change significantly over time; it changed from a mean of 7.9/1,000 discharges in 2002 to 6.7 (2003), 8.2 (2004), 6.2 (2004), 6.2 (2005), and 5.2/1,000 discharges in 2006 (P = 0.50). There were significant linear relationships between total carbapenem use and incidence rates of carbapenem-resistant P. aeruginosa in 2002 (adjusted $R^2 = 0.47, P = 0.0038$), 2003 (adjusted $R^2 = 0.37, P = 0.003$), and 2004 (adjusted $R^2 = 0.18, P = 0.033$); the relationship was not significant thereafter. The linear relationships between carbapenem use and the proportion of resistant P. aeruginosa isolates were positive for all years, but were not statistically significant (data not shown).

Hospitals that restricted carbapenems used significantly fewer carbapenems than hospitals that did not restrict for all 5 years ($P = 0.04$) (Fig. 1). In addition, the incidence rates of
carbapenem-resistant *P. aeruginosa* in hospitals that restricted carbapenems were significantly lower for all 5 years compared with those that did not restrict (*P* = 0.01) (Fig. 1). Whereas the mean proportion of resistant *P. aeruginosa* isolates was consistently lower for all 5 study years in hospitals that restricted carbapenems than that of hospitals that did not restrict, these differences were not statistically significant (data not shown).

The mean total fluoroquinolone use in hospitals that restricted carbapenems was consistently lower, by approximately 20 DDD/1,000 PD, depending upon the year, than that of hospitals that did not restrict carbapenems (data not shown). There was no significant linear relationship between total fluoroquinolone use and incidence rates of carbapenem-resistant *P. aeruginosa* for any of the 5 years of study.

When excluding the three hospitals that did not remove duplicate isolates when compiling susceptibility analyses and the four hospitals for which the duplicate isolate policy was unknown, results of the mixed model analyses did not change.

**DISCUSSION**

The National Nosocomial Infections Surveillance (NNIS) system reported that the percentage of *P. aeruginosa* isolates resistant to imipenem rose 15% from the time period 1998 to 2002 compared to the final study year, 2003 (3). The causes of this are not known but may in part be related to differences in levels of carbapenem use in NNIS hospitals during this period. Some hospitals restrict the use of carbapenems as an antimicrobial stewardship strategy, as seen in this investigation, yet few studies have examined the effect of restriction on carbapenem use or resistance, and to our knowledge there are no previous multicenter investigations of this issue. Bantar et al. (1) developed an intervention program to optimize hospital antibacterial use and demonstrated a statistically significant decrease in carbapenem use over a 2-year period (from 13.5 to 6.2 DDD/1,000 PD; *P* = 0.03). This was associated with a significant decrease in the proportion of imipenem-resistant *P. aeruginosa* isolates, from 19% to 0%. White and colleagues (22) studied the effect of an antimicrobial control program on antimicrobial expenditures and susceptibilities. Monthly expenditures for imipenem during the program decreased by 40%, and the proportion of *P. aeruginosa* isolates susceptible to imipenem increased significantly, from 83% to 95% for inpatients and from 65% to 83% for intensive care unit patients. Martin et al. (11) described an antimicrobial stewardship program that restricted the use of carbapenems and found that carbapenem susceptibilities for *P. aeruginosa* improved over 5 years, from 86% for the first year of the study to 91% in the last year. Carbapenem use was variable throughout the study period and actually increased from the first study year to the final year.

The present study examined a relatively large cohort of academic health centers over a 5-year period and observed that hospitals that restricted the use of carbapenems used significantly fewer of these agents and had significantly lower incidence rates of resistance among *P. aeruginosa* isolates. There was not a statistically significant difference in the proportions of carbapenem-resistant *P. aeruginosa* isolates between hospitals that restricted carbapenems and those that did not, although hospitals that restrict carbapenems had lower proportions of resistance for each study year. The lack of significance in the analysis of the proportion of resistance may in part be due to the relatively few hospitals that restricted carbapenems and insufficient statistical power. On the other hand, the method or measuring resistance is taking on increasing importance. Schwaber has argued that the use of proportions of resistant organisms to assess the impact of antibacterial use can be misleading since proportions are dependent on the susceptible and resistant bacterial populations, whereas the incidence rate of resistance depends only upon the resistant population (17). Antibacterial use likely leads to a decrease in the absolute number of susceptible organisms, which results in an increase in the proportion of isolates that are resistant. This does not necessarily translate to an increase in the absolute number of resistant isolates or the burden of resistance. Cook assessed the impact of ciprofloxacin restriction on both proportion and incidence rates of resistant nosocomial isolates of *P. aeruginosa* (4). He found that ciprofloxacin use declined by 57% and that both incidence rates and the proportion of ciprofloxacin-resistant *P. aeruginosa* isolates declined significantly. However, imipenem/meropenem use increased over the same time period, as did the incidence rates and proportions of carbapenem-resistant *P. aeruginosa* isolates. Rogues reported a stronger relationship between antibiotic use (as DDD/1,000 PD) among 47 French hospitals and incidence rates of methicillin-resistant *Staphylococcus aureus* (MRSA) and drug-resistant *P. aeruginosa* than between antibiotic use and proportions of these resistant organisms (16). Burton also reported that the incidence rates of MRSA bacteremia in patients with central lines from 1,684 U.S. intensive care units monitored by the Centers for Disease Control and Prevention decreased by nearly 50% over the 10-year period 1997 to 2007 (2). When the same data were expressed as a proportion (percent), there was an apparent increase of 25% in MRSA bloodstream infections. The association between antibiotic use and incidence rates versus proportion of resistant organisms deserves additional investigation.

There are limitations to this study. First, we examined aggregated hospital-level data; this “ecologic bias” does not necessarily reflect antibacterial use and resistance patterns at the patient level (9). While our results cannot prove a causal relationship between carbapenem restriction policies, lower carbapenem use, and lower incidence rates of carbapenem-resistant *P. aeruginosa*, the association was relatively large, statistically significant, and persistent over time. Turnidge has argued that when these aggregate-level “correlations” are statistically significant, they are likely of importance and suggest that a reduction in consumption of the correlated antibiotic class will reduce resistance (21). It is also noteworthy that simple univariate associations between carbapenem use and incidence rates of carbapenem resistance were relatively strong and significant in the early years of this investigation, but the strength of these associations subsided with time. This shift emphasizes the need to examine these relationships for more than a single year or single point in time. Second, we did not measure hospital infection control measures, and it is possible that hospitals that restrict carbapenems also have more stringent infection control practices, leading to lower incidence rates of carbapenem resistance. Third, while we were able to separate carbapenem use with adults from use with patients
less than 18 years of age, we were not able to separate clinical
isolates of \textit{P. aeruginosa} by patient age. Consequently, the
microbiological end points in this investigation are a mix of
adult and pediatric data, potentially weakening the association
between adult antibiotic use and resistant \textit{P. aeruginosa} in
adults. Finally, carbapenem resistance in \textit{P. aeruginosa} is more
complex than simply carbapenem use and cross-transmission,
and many additional risk factors have been reported from
case-control investigations (8, 13). Many of these carbapenem-
resistant isolates are likely to be multidrug resistant (5), and
the use of other antimicrobials—in particular the fluoroquino-
lones—has been found to select for carbapenem resistance (5,
13, 14). Consequently, hospitals in this investigation that re-
stricted the use of carbapenems may use relatively larger
amounts of other, nonrestricted drugs, possibly increasing
rates of resistance to those agents or even to the restricted
agent. This phenomenon has been referred to as “squeezing
the balloon” (14). However, we did not find fluoroquinolone
use in hospitals that restricted carbapenems to be higher than
that in hospitals that did not restrict carbapenems, nor did we
find significant linear relationships between fluoroquinolone
use and incidence rates of carbapenem-resistant \textit{P. aeruginosa}.
We did not attempt to incorporate the use of other antibacte-
rial classes in the present assessment, and it is not yet possible
to model all of these complex, competing, and possibly con-
 founding relationships.

These data suggest that restricting carbapenems may be an
effective element in an overall strategy for addressing the prob-
lem of carbapenem resistance in \textit{P. aeruginosa}. Of equal or
greater concern is the emergence of carbapenemase produc-
tive organisms, and preserving the effectiveness of available
antibacterial resistance (19).

\section*{Acknowledgments}

We thank UHC CRM member participants, including pharmacists,
 microbiologists, and infectious disease physicians for their willingness
to provide the data necessary to conduct this study.

This work was supported by Virginia Commonwealth University
A. D. Williams Trust Funds.

Potential conflicts of interest include the following: R.E.P. received
research funding from Merck and Co., ViroPharma Inc., and Bayer
Pharma (grant support assumed by Schering-Plough) and is on the
Schering-Plough Speakers Bureau; and A.L.P. received an honorarium
from Schering-Plough for an oral presentation and grant support from
ViroPharma, Inc. M.O. has no potential conflicts to report.

\section*{References}

Oliva. 2003. A hospital-wide intervention program to optimize the quality of
antibiotic use: impact on proscribing practice, antibiotic consumption, cost
2009. Methicillin-resistant \textit{Staphylococcus aureus} central line-associated
bloodstream infections in US intensive care units, 1997–2007. JAMA 301:
727–736.
32:470–485.
program to reduce hospital cephalosporin use on nosocomial \textit{Pseudomonas aeruginosa} susceptibility to quinolones and other antimicrobial agents.
5. D’Agata, E. M. C., M. A. Cataldo, R. Cauda, and E. Tacconelli. 2006. The
importance of addressing multidrug resistance and not assuming single-drug
674.
7. Deliti, T. H., R. C. Owens, J. E. McGowan, D. N. Gerding, R. A. Weinstein,
J. P. Burke, W. C. Huskings, D. L. Paterson, N. O. Fishman, C. F. Carpenter,
P. J. Brennan, M. Billeter, and T. M. Hooton. 2007. Infections Diseases
Society of America and the Society for Healthcare Epidemiology of America
Guidelines for developing an institutional program to enhance antimicrobial
multi-drug-resistant \textit{Acinetobacter baumannii} and \textit{Pseudomonas aeruginosa}; a
analysis of individual and aggregated data on antibiotic exposure and resis-
model and repeated measures ANOVA using a dataset with multiple missing
Hoven, and M. Evans. 2005. Results of an antimicrobial control program at a
Acquisition of multidrug-resitant \textit{Pseudomonas aeruginosa} in patients in
14. Peterson, L. R. 2005. Squeezing the antibiotic balloon: the impact of anti-
54–56.
antibiotic usage in 130 US hospitals: comparison of defined daily dose
(DDD) to duration of therapy (DOT)/1000 patient days (PD). Clin. Infect.
rein, and J. P. Gachie. 2007. Relationship between rates of antimicrobial con-
sumption and the incidence of antimicrobial resistance in \textit{Staphylococcus}
and \textit{Pseudomonas aeruginosa} isolates from 47 French hospitals. Infect. Control
interpretation of antibiotic resistance studies—what are we missing? Nat.
Rev. 2:979–983.
acea}: a potential threat. JAMA 300:2911–2912.
infections: a call to action for the medical community from the Infectious
producing organisms: an ounce of prevention really is worth a pound of cure.
proving the obvious. Lancet 365:548–549.
22. White, A. C., Jr., R. L. Atmar, J. Wilson, T. R. Cate, C. E. Stager, and S. B.
Greenberg. 1997. Effects of requiring prior authorization for selected anti-
Dis. 25:230–239.